THINK-TANK MEETING

AN IN DEPTH LOOK AT TRENDS IN POLY-TARGETED LUNG CANCER THERAPY

Institut Germans Trias i Pujol (IGTP), Conference Meeting Room, Badalona, Barcelona, Spain - June 15th 2016

Rafael Rosell on behalf of all the investigators

Graphical Abstract

Highlights:

EGFR TKIs induce early STAT3 activation and other signaling pathways. Cross-talk between different signaling pathways is the basis for poly-therapy in EGFR mutated driven lung cancer as well as in KRAS driven lung adenocarcinoma, squamous cell carcinoma of the lung and other tumors.
PROGRAM

08:30-9:00: Reception

09.00-09:10: Welcome and introduction

SESSION I

POLY- THERAPY IN SQUAMOUS CELL CARCINOMA OF THE LUNG AND IN KRAS DRIVEN LUNG ADENOCARCINOMA.

Chairpersons: Niki Karachaliou, Claudio Dazzi and Filippo de Marinis

- Aberrations on the EGFR pathway in squamous cell carcinoma cell lines
- Co-targeting YAP/STAT3, PAK1, AXL, and Hedgehog
- In vitro findings in squamous cell carcinoma cell lines
  - Alberto Verlicchi, Santa Maria delle Croci, Ravena, Italy

09:35-10:00: Poly-therapy in KRAS mutant driven lung adenocarcinoma
- Tracking biomarkers beyond RAS downstream signaling
- Selumetinib-based therapy co-targeting STAT3/YAP, AXL and PAK1
- The need for MET inhibition
- In vitro findings in KRAS mutant driven NSCLC cell lines
  - Chiara Lazzari, European Institute of Oncology (IEO), Milan, Italy

10:00-10:15: Cutting edge treatment in squamous cell lung cancer
  - Claudio Dazzi, Santa Maria delle Croci, Ravena, Italy

10:15-10:30: State of art treatment in KRAS mutant NSCLC
  - Filippo de Marinis, European Institute of Oncology (IEO), Milan, Italy

10:30-11:00: Open comments

11:00-11:30 Coffee break
SESSION II

POLY-THERAPY FOR EGFR MUTANT NSCLC

Chairpersons: Rafael Rosell and Imane Chaib

11:30 – 12:00: Co-activation of signal transducer and activator of transcription 3 (STAT3) and YES-associated protein 1 (YAP1) pathway in EGFR mutant non-small-cell lung cancer

- Niki Karachaliou, Hospital Sagrat Cor, Barcelona, Spain

12:00-12:30: Tracking signaling pathways in EGFR mutant lung cancer cell lines. Findings from in vitro experiments and western blotting

- Imane Chaib, Institut Germans Trias I Pujol (IGTP), Badalona, Barcelona, Spain

13:00 – 13:30: Developing novel targeted therapies in NSCLC

- Enriqueta Felip, Institut d’Oncologia, Vall d’Hebron, Barcelona, Spain

13:30-14:00: Moving forward in cancer

- Rafael Rosell, Catalan Institut of Oncology (ICO), Badalona, Barcelona, Spain

14:00-14:30: Lunch

SESSION III

LUNG CARCINOGENESIS, CANCER STEM CELLS AND PROTEIN TYROSINE PHOSPHATASES

Chairperson: Miguel Angel Molina, PB, Barcelona, Spain and Jose Luis Ramirez

14:40 – 15:00 Cancer stem cells in EGFR mutant NSCLC

- Jordi Codony and Carles Codony, Breakthrough Cancer Research Unit, PB, Barcelona, Spain

15:00 – 15:20 Mutational status of PTPRT and relationship with STAT3 activation

- Jose Luis Ramirez, Catalan Institut of Oncology (ICO), Badalona, Barcelona, Spain

15:20 – 15:50 Searching for new lung cancer molecular key players with a multiplatform approach

- Luis M. Montuenga, Center for Applied Medical Research (CIMA), Pamplona, Spain

16:00: Closing remarks
How to get to the IGTP/IMPPC

By car / taxi:
We are 20 minutes from the center of the city and the most convenient way to arrive is by car or taxi. We are close to the Hospital which can serve as a good point of reference:

Hospital Universitari Germans Trias I Pujol (Popularly known as Can Rutí)
GPS: 41°29’06.66”N 2°14’21.27”E

From Barcelona take B20 (Rondas and Nus de la Trinitat) in direction Mataró. The hospital is well signed from the exit 21 (Badalona Centre) of the B20.